Финлепсин Drug photo

The description is actual on 14.12.2014

  • Latin name: Finlepsin
  • ATH code: N03AF01
  • Active ingredient: Carbamazepine (Carbamazepine)
  • Producer: 1.Teva, Israel. 2. AWD.pharma, Germany.


Tablets contain active component: carbamazepine – 200 mg.

Additional components: MKTs, gelatin, croscarmellose sodium, magnesium stearate.

Release form

Finlepsinum in the form of the tablets packaged in blisters on 10 pieces, on 3, 4 or 5 blisters in a pack is issued.

Pharmacological action

The tablets Finlepsinum possess antiepileptic, antipsychotic and analgeziruyushchy action.

Pharmacodynamics and pharmacokinetics

For this antiepileptic means, to being dibenzazepine derivatives, the antidepressive, antipsychotic, antidiuretic and analgeziruyushchy effect is also characteristic. Effect of drug is related to the blockade of potentsialzavisimy natrium channels promoting stabilization of membranes of the overexcited neurons, lowering of synoptic carrying out impulses and inhibition of serial categories of neurons. Release of neuromediator amino acid – a glutamate, possessing exciting action that promotes decrease in a convulsive threshold of a nervous system, and, therefore, and probabilities of emergence of an epileptic attack is reduced.

Efficiency of drug is shown at simple or complex epileptic attacks which can be followed by secondary generalization and so on. At the same time decrease in symptoms of uneasiness, a depression, irritability and aggression is noted.

The slow, but full absorption which is not depending on the use of food is inherent to this drug. Concentration of substance in an organism is reached during 12 h at single use Finlepsinum retard 400 mg, keeping a therapeutic effectiveness of 4-5 h. At the same time equilibrium concentration of active agent as a part of plasma are reached after a therapeutic course of 1-2 weeks. However it can depend on features of a metabolism of the patient: autoinduktion of fermental systems in a liver, heteroinduction the other, at the same time taken medicine, conditions of the patient, a dosage and duration of treatment. It is established that carbamazepine gets into breast milk and through a placental barrier.

The metabolism of drug happens in a liver to formation of the main metabolites: carbamazepine-10,11-epoxide – active action and an inactive conjugate with glucuronic acid. As a result of metabolic process less active metabolite 9-hydroxy-methyl-10-karbamoilakridan capable to induce own metabolism is formed. Removal of drug is mainly carried out as a part of urine, part – with a stake.

Indications to use of Finlepsinum

The main indications to use of Finlepsinum:

  • various forms of epilepsy;
  • neuralgia;
  • pain at nervous disturbances at patients with a diabetes mellitus;
  • different types of convulsive states – spasms, attacks and so on;
  • syndrome of alcoholic abstinence;
  • psychotic frustration.

Contraindications to use

Finlepsinum is not appointed at:

  • hypersensitivity to its components or tricyclic antidepressants;
  • disturbances of a marrowy hemopoiesis;
  • the acute alternating porphyria;
  • AV to blockade;
  • concomitant use of drugs of lithium or MAO inhibitors.

It is recommended to be careful at treatment of patients with dekompensirovanny chronic heart failure, a cultivation hyponatremia, disturbances of a liver and kidneys, advanced age, active alcoholism, oppression of a marrowy hemopoiesis, during reception of some drugs, a prostate hyperplasia, increase of intraocular pressure and so on.

Side effects of Finlepsinum

As a rule, side effects at treatment by this drug can develop because of exceeding of a dosage or considerable fluctuations in concentration of active agent in an organism. Emergence of deviations in work of a nervous system is in most cases noted: dizzinesses, ataxy, drowsiness, general weakness, headache and so on. Manifestation of allergic reactions, for example, of the small tortoiseshell, erythroses, skin rashes and other symptoms is also possible.

The system of a hemopoiesis and blood can react with emergence: leukopenias, thrombocytopenia, eosinophilia, leukocytosis, limfoadenopatiya. The probability of development of deviations in work of a gastrointestinal tract remains: nausea, vomitings, dryness in a mouth, increases of activity gamma glutamiltransferazy, activity and hepatic transaminases, diarrhea or a lock.

Besides, disturbances, work-related endocrine system and a metabolism can be shown: puffiness, liquid delay, increase of body weight, vomiting, hyponatremia and other. It is not necessary to exclude development of deviations of functions of cardiovascular and urinogenital systems, a musculoskeletal system and sense bodys.

Tablets Finlepsinum, application instruction (Way and dosage)

This medicine is intended for intake, irrespective of the use of food.

At treatment of epilepsy of a tablet are appointed in the form of monotherapy. If Finlepsinum is attached to antiepileptic therapy, then carry out it gradually, strictly controlling dosages. In cases when reception of a tablet is missed, it needs to be accepted at once as omission will be shown, but it is not necessary to fill the admission with a double dose.

As the application instruction reports Finlepsinum retard, to adult patients in an initiation of treatment appoint a daily dose of 200-400 mg. Then perhaps gradual increase in a dosage allowing to reach optimum efficiency. The supporting daily dose makes – 800-1200 mg, at the same time this quantity is divided into 1-3 receptions. The most admissible daily dose should not exceed 1,6–2 g.

For children the dose of drug depends on age. Besides, when it is difficult to child to take the whole pill, it can be chewed, crushed and dissolved in the small volume of liquid.

To children of 1-5 years appoint 100–200 mg, increase gradually daily dosage to reach optimal effect.

To children of 6-10 years recommend to begin to treat from a daily dosage Finlepsinum retard 200 mg, then also gradually raise a dose.

The initial daily dosage for children of 11-15 years makes 100-300 mg. Then it is gradually increased on 100 mg, the optimum effect will not be shown yet.

The average supporting daily doses: for little patients of 1-5 years – 200–400 mg, 6–10 years within 400–600 mg, 11-15 years – 600-1000 mg which divide into several receptions.

Duration of treatment has direct dependence on the indication and specific features of the patient. Anyway all decisions connected with therapy remain in competence of the doctor. Usually the question of a dose decline or drug withdrawal is discussed when the patient has no attacks during 2-3 flyings.

The termination of treatment assumes the gradual dose decline proceeding 1-2 years under regular control of EEG. At the same time at children it is necessary to consider the increasing weight and age.

During treatment of other disturbances according to indications, the dosage and duration of reception are established by the doctor, considering complexity of a disease and feature of the specific patient.


At overdose by Finlepsinum various symptoms indicating disturbance of work of nervous, cardiovascular and respiratory systems, sense bodys and general deviations can develop.

It is shown: oppression of the TsNS functions, disorientation, drowsiness, excitement, hallucinations, coma, sight zatumanennost, tachycardia, failure of the ABP, faints, breath disturbances, fluid lungs, nausea, vomiting, ischuria and so on.

It is established that for overdose treatment the antidote is absent therefore the supporting treatment depending on the shown symptoms is carried out, in difficult cases – in the conditions of a hospital.


The combination of this drug to CYP3A4 inhibitors causes increase of concentration of carbamazepine as a part of a blood plasma and development of undesirable reactions. The combination with the inductors CYP3A4 often accelerates a carbamazepine metabolism, reducing its concentration and therapeutic effect.

Simultaneous use of verapamil, diltiazem, felodipin, dextropropoxyphene, viloksazin, fluoxetine, fluvoksamin, Cimetidinum, acetazoleamide, danazol, desipramine, nikotinamid, and also macroleads – erythromycin, a dzhozamitsin, a klaritromitsin, a troleandomitsin, some azoles – an itrakonazol, a ketokonazol and a flukonazol can increase concentration of carbamazepine considerably. The same action is characteristic of a terfenadin, a loratadin, an isoniazid, the propoxyhair dryer, grapefruit juice, inhibitors of virus protease. At the same time correction of a dosage and control of concentration of substance in plasma is necessary.

The combination of a felbamat and carbamazepine can lead to mutual lowering or increase of concentration.

Can lower concentration of carbamazepine also: phenobarbital, Primidonum, metsuksimid, Phenytoinum, fensuksimid, theophylline, Cisplatinum, doxorubicine, rifampicin, clonazepam, valproic acid, valpromid, okskarbazepin and a number of vegetable drugs which contain the St. John's Wort which is made a hole.

Carbamazepine reduces concentration in plasma of such drugs as: to klobaza, clonazepam, an Ethosuximidum, Primidonum, digoxin, valproic acid, to alprazola, cyclosporine, tetracycline, a haloperidol, peroral drugs with the content of estrogen and progesterone and so on.

It is established that tetracyclines weaken medical effect of carbamazepine. Use with paracetamol increases risk of toxic impact on a liver, reducing a therapeutic effectiveness. The combination to fenotiazina, Pimozidum, molindony, Clozapine, a haloperidol, thioxanthenes, Maprotilinum and tricyclic antidepressants strengthens the oppressing influence on a nervous system, weakening anticonvulsant effect of drug.

Therefore when to patients Finlepsinum is appointed, it is necessary to report to the doctor about what drugs still they accept at once.

Terms of sale

Finlepsinum is released strictly according to the recipe.

Storage conditions

Storage of tablets requires the dark, cool place protected from children.

Period of validity

3 years.

Analogs of Finlepsinum

Coincidence on the ATH code of the 4th level:

The main analogs of Finlepsinum are provided by drugs: Aktinerval, Apo-Karbamazepin, Zagretol, Zeptol, Karbalepsin retard, Carbamazepine, Mazepin, Stazepinum, Storilat, Tegretolum and others.


It is established that carbamazepine reduces portability of ethanol. But also taking alcohol during diseases at which this drug is shown, it is possible to expect development of side effects and various complications.


  • Finlepsinum retard 200 mg No. 50 tabletkiteva Pharmaceutical
  • Finlepsinum of 200 mg No. 50 tabletkiteva Pharmaceutical
  • Finlepsinum retard 400 mg No. 50 tabletkiteva Pharmaceutical

Drugstore of IFC

  • Finlepsinum tbl 200 mg No. 50 *, Teva Opereyshns Poland Sp. z lake of the lake Poland
  • Finlepsinum Retard tbl 200 mg No. 50 *, Teva Opereyshns Poland Sp. z lake of the lake Poland
  • Finlepsinum Retard tbl 400 mg No. 50, Teva Opereyshns Poland Sp. z lake of the lake Poland
to show still


  • Finlepsinawd. pharma (Germany)
  • Finlepsinum retardawd. pharma (Germany)
  • Finlepsinum retardawd. pharma (Germany)


  • Finlepsinum retard tablets 200 of mg No. 50TEBA
  • Finlepsinum retard tablets 200 of mg No. 50TEBA
  • Finlepsinum retard tablets 200 of mg No. 50TEBA


  • Finlepsinum of 400 mg No. 50 of the tab. retardavd. a farma Gmbh and To. KG, Germany, proizv. Pliva Krakov, A.O Pharmaceutical plant. (Poland)
  • Finlepsinum of 200 mg No. 50 of the tab. retardavd. a farma Gmbh and To. KG, Germany, proizv. Pliva Krakov, A.O Pharmaceutical plant. (Poland)
  • Finlepsinum of 200 mg No. 50 of the tab. of Teva Operations Poland Sp. z.o.o. (Poland)
to show still
Section: For a nervous system
PAY ATTENTION! Information on drugs on the website is help generalizing, collected from public sources and can form the basis for making decision on use of medicines it is not aware of treatment. Before medicine use Finlepsinum surely consult with the attending physician.